## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

FELD Yair et al

Serial No.:

09/691,889

Filed:

October 20, 2000

Nucleic Acid Constructs And Cells, And Methods For: Utilizing Same For Modifying The Electrochemical Condu

Of Excitable Tissues

Examiner:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit:

Attorney

Docket: 00/20989

## INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is being filed subsequent to the issuance of an Office Action and the amount of \$180.00 is due therefor.

Authorization to charge the above late fee of \$180.00 to the Credit Card number listed on the attached Credit Card Payment Form PTO-2038 is attached herewith. In the event additional fees are required, please charge these additional fees to Deposit Account 50-1407. In the unlikely event payment by the Credit Card issuer is refused, please charge the late fee of \$180.00 to Deposit Account 50-1407.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Sol Sheinbein
Registration No. 25,457

DEC 3 0 2004

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 09/691,889 Filing Date October 20, 2000 INFORMATION DISCLOSURE First Named Inventor FELD Yair et al STATEMENT BY APPLICANT Art Unit 1632 Examiner Name Falk (use as many sheets as necessary) Attorney Docket Number 00/20989 3 Sheet **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Where Examiner Cite Document Number Publication Date Name of Patentee or Initials\* MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code<sup>2</sup> (1f known) 11-17-1998 Blake et al. US-5,837,220 Holmes et al. 09-21-1999 2 US-5,955,259 01-11-2000 3 US-6,013,766 Elgoyhen et al. 4 US-6,087,488 07-11-2000 Ganetzky et al. 5 US-6,100,046 08-8-2000 Elgoyhen et al.

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Foreign Patent Documents  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	6	WO02/087419	11-07-2002	Marban et al				
	7	WO00/63434	10-26-2000	Abbott et al			-	
							<u> </u>	
							+	
Examiner Signature			<b></b>		Date Considered			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

,		Act of 1995, no persons are required by respond to a collect		Complete	if Known			
	Substitute for form 1449A/PTO				09/691	9/691,889		
	INF	DRMATION DISCLOSURE	Filing Date	October 20, 2000				
STATEMENT BY APPLICANT				First Named Inventor	FELD	Yair et al		
	SIA	TEMENT DI ATTEMANT		Group Art Unit				
	(	(use as many sheets as necessary)		Examiner Name				
Sheet	2 Of 3			Attorney Docket Number 00/20989		89		
		OTHER PRIOR ART – NON PA						
Examiner Initials	Cite No. <sup>1</sup>							
	8	Feld et al. "Electrophysiological Modulation of Cardiomyocytic Tissue by Transfected Fibroblasts Expressing Potassium Channels: A Novel Strategy to Manipulate Excitability", Circulation 105(4): 522-9, 2002.						
-	9	Hammond et al. "Angiogenic Gene Therapy for Heart Disease: A Review of Animal Studies and Clinical Trials", Cardiovasc Res 49(3): 561-7, 2001.						
	10	DeGroot et al. "Clinical Review 131: Gene Therapy for Thyroid Cancer: Where Do We Stand?", J Clin Endocrinol Metab 86(7): 2923-8, 2001.						
	11	Siegel "Biotechnology and Clinical Tria	Siegel "Biotechnology and Clinical Trials", J Infect Dis 185(Suppl 1): S52-7, 2002.					
	12	Reinlib et al. "Cell Transplantation as Future Therapy for Cardiovascular Disease?: A Workshop of the National Heart, Lung, and Blood Institute", Circulation 101(18): E182-7, 2000.						
-	13	Roth et al. "Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients With Severe Hemophilia A", N Engl J Med 344(23): 1735-42, 2001.						
	14	Fast et al, "Anisotropic conduction in monolayers of neonatal rat heart cells cultured on collagen substrate", Circ Res. 1994 Sep;75(3):591-5.						
	15	Marshall "Gene Therapy's Growing Pains", Science 269: 1050-1055, 1995.						
	16	Verma et al. "Gene Therapy - Promises, Problems and Prospects", Nature 389(6648): 239-42, 1997.						
	17	Johns et al, "Adenovirus-mediated expression of a voltage-gated potassium channel in vitro (rat cardiac myocytes) and in vivo (rat liver). A novel strategy for modifying excitability.", J Clin Invest. 1995 Aug;96(2):1152-8.						
	18	Nuss et al, "Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes", J Clin Invest. 1999 Mar;103(6):889-96.						
	19	Donahue et al, "Focal modification of electrical conduction in the heart by viral gene transfer", Nat Med. 2000 Dec;6(12):1395-8.						
	20	Miller et al. "Targeted Vectors for Gene Therapy", FASEB J. 9(2): 190-9, 1995.						
	21	Orkin et al. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy": 1-40 1995, + http://.nih.gov/news/panelrep.html (1975).						
	22	Koh et al. "Differentiation and Long-Term Survival of C2C12 Myoblast Grafts in Heart", J Clin Invest 92(3): 1548-54, 1993.						
	23							
				Considered				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it contains a valid OMB control number

Under the Pape	erwork Reduction	n Act of 1995, no persons are required to respond to a collection of information unl	Complete if Known				
	Su	ubstitute for form 1449A/PTO	Application Number	09/691,889			
	INF	ORMATION DISCLOSURE	Filing Date	October 20, 2000			
		ATEMENT BY APPLICANT	First Named Inventor	FELD Yair et al			
	<b>51</b> P	ALEMENT BY APPLICANT	Group Art Unit				
		(use as many sheets as necessary)	Examiner Name	· · · · · · · · · · · · · · · · · · ·			
Sheet	3	Of 3	Attorney Docket Number	00/20989			
	22	Rook et al, "Differences in gap junction channels between					
	l	fibroblasts, and heterologous pairs", Am J Physiol. 199	92 Nov;263(5 Pt 1):C959-	-77.			
	23	ed in Duchenne Muscular					
		Dystrophy Patients After Myoblast Transplantation", Nature 356(6368): 435-8, 1992.  Freed et al. "Survival of Implanted Fetal Dopamine Cells and Neurologic					
	24						
		Improvement 12 to 46 Months After Transplantation for Parkinson's Disease", N					
		Engl J Med 327(22): 1549-55, 1992.					
	25	Jockusch et al. "Long-Term Expression of Isomyosins	and Myoendocrine Funct	ions			
		in Ectopic Grafts of Atrial Tissue", Proc Natl Acad Sci USA 83(19): 7325-9, 1986.					
	26	Bader et al. "Repair and Reorganization of Minced Cardiac Muscle in the Adult Newt					
		(Notophthalmus Viridescens)", J Morphol 155(3): 349					
	27	Lerche et al. "Ion Channels and Epilepsy", Am J Med Genet 106(2): 146-59, 2001.					
	28	Luo et al. "A Model of the Ventricular Cardiac Action Potential. Depolarization, Repolarization, and Their Interaction", Circ Res 68(6): 1501-26, 1991.					
	29	Marom et al. "Modeling State-Dependent Inactivation	of Membrane Currents",				
		Biophys J. 67(2): 515-20, 1994.					
	30	Marom "Slow Changes in the Availability of Voltage-Gated Ion Channels: Effects on					
		the Dynamics of Excitable Membranes", J Membr Bio					
	31	Marom et al. "State-Dependent Inactivation of the Kv3	Potassium Channel",				
		Biophysical Journal 67: 579-589, 1994.					

Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 1.22 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.